Skip to main content
Top
Published in: Clinical Rheumatology 9/2018

01-09-2018 | Original Article

Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM)

Authors: Sümeyye Merve Türk, Döndü Üsküdar Cansu, Hava Üsküdar Teke, Timuçin Kaşifoğlu, O. Meltem Akay, Muzaffer Bilgin, Cengiz Korkmaz

Published in: Clinical Rheumatology | Issue 9/2018

Login to get access

Abstract

The higher incidence of arterial and venous events is well established in patients with rheumatoid arthritis (RA). Our aim here was to investigate whether there is a prothrombotic state in RA patients by using rotational thromboelastometry (ROTEM) method and to demonstrate whether the disease variables play a role in this process. A total of 85 patients who met the 2010 RA classification criteria were consecutively included in the study. The patients with RA who have been using antiaggregant, anticoagulant, or nonsteroidal anti-inflammatory drugs (NSAIDs) and had a history of arterial or venous thromboembolism were excluded from the study. Their complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, D-dimer, and lipid profiles were measured, DAS-28 disease activation scores were calculated, and simultaneous ROTEM analysis was performed to determine the predisposition to thrombosis. Of the ROTEM parameters, clotting time (CT, seconds (s)), clot formation time (CFT, s), and maximum clot firmness (MCF) were evaluated. Having a shorter CT and/or CFT in intrinsic (I) or extrinsic (E) pathway and/or a longer MCF compared to the healthy controls was considered as “predisposition to hypercoagulability”. The mean age of the 85 RA patients were 54.12 ± 13 years, and 77.6% of the patients were female (n = 66). Of the patients, 52.9% (n = 45) were using methotrexate (MTX) ± hydroxychloroquine (HCQ) ± corticosteroid (CS), while 43.5% (n = 37) were using anti-tumor necrosis factor (TNF) ± MTX. Active steroid usage was ongoing in 64.7% of the patients (n = 55). When evaluated according to DAS-28, in those with higher disease activity, a shorter I-CFT and greater I-MCF were determined (p = 0.020 and p = 0.033, respectively). In those with higher disease activity based on the correlation analysis, I-CFT and E-CFT were shorter and I-MCF and E-MCF were longer, indicating a higher predisposition to thrombosis. Using linear regression, variables with a major effect on ROTEM parameters were identified as DAS-28, CRP, and platelet count. As the first study in the literature, we identified that disease activation is the most important risk factor for prothrombotic state in RA patients irrespective of the drugs used. ROTEM can be used in clinical practice to predict thrombotic events in RA patients.
Literature
1.
go back to reference Brasington RD (2011) Rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weismna MH (eds) Rheumatology. Philadelphia:Elsevier, pp 829–838CrossRef Brasington RD (2011) Rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weismna MH (eds) Rheumatology. Philadelphia:Elsevier, pp 829–838CrossRef
2.
go back to reference Liang KP, Liang KV, Matteson EL, Mcclelland RL, Christianson TJ, Turesson C (2006) Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 54:642–648CrossRefPubMedPubMedCentral Liang KP, Liang KV, Matteson EL, Mcclelland RL, Christianson TJ, Turesson C (2006) Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 54:642–648CrossRefPubMedPubMedCentral
3.
go back to reference Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL (2012) Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 64:53–61CrossRefPubMedPubMedCentral Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL (2012) Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 64:53–61CrossRefPubMedPubMedCentral
4.
go back to reference Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, Sung FC, Kao CH (2014) Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 73:1774–1780CrossRefPubMed Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, Sung FC, Kao CH (2014) Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 73:1774–1780CrossRefPubMed
5.
go back to reference Mameli A, Barcellona D (2009) Marongiu F (2009). Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 27:846–855PubMed Mameli A, Barcellona D (2009) Marongiu F (2009). Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 27:846–855PubMed
6.
go back to reference van den Oever IA, Sattar N, Nurmohamed MT (2014) Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 73:954–957CrossRefPubMed van den Oever IA, Sattar N, Nurmohamed MT (2014) Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 73:954–957CrossRefPubMed
7.
go back to reference Aksu K, Donmez A, Keser G (2012) Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 18:1478–1493CrossRefPubMed Aksu K, Donmez A, Keser G (2012) Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 18:1478–1493CrossRefPubMed
8.
go back to reference Whiting D, DiNardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89:228–232CrossRefPubMed Whiting D, DiNardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89:228–232CrossRefPubMed
9.
go back to reference Akay OM, Ustuner Z, Canturk Z, Mutlu FS, Gulbas Z (2009) Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol 26:358–364CrossRefPubMed Akay OM, Ustuner Z, Canturk Z, Mutlu FS, Gulbas Z (2009) Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol 26:358–364CrossRefPubMed
10.
go back to reference Yaşar Bilge NŞ, Akay OM, Kaşifoğlu T, Kuş G, Korkmaz C (2013) The role of hemostatic mechanisms in the development of thrombosis in Behcet's disease: an analysis by modified rotation thromboelastogram (ROTEM). Clin Rheumatol 32:1815–1818CrossRefPubMed Yaşar Bilge NŞ, Akay OM, Kaşifoğlu T, Kuş G, Korkmaz C (2013) The role of hemostatic mechanisms in the development of thrombosis in Behcet's disease: an analysis by modified rotation thromboelastogram (ROTEM). Clin Rheumatol 32:1815–1818CrossRefPubMed
11.
go back to reference Collins KS, Balasubramaniam K, Viswanathan G, Natasari A, Tarn J, Lendrem D, Mitchell S, Zaman A, Ng WF (2013) Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjogren’s syndrome. BMJ Open 3:e002739CrossRefPubMedPubMedCentral Collins KS, Balasubramaniam K, Viswanathan G, Natasari A, Tarn J, Lendrem D, Mitchell S, Zaman A, Ng WF (2013) Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjogren’s syndrome. BMJ Open 3:e002739CrossRefPubMedPubMedCentral
12.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed
13.
go back to reference Goren Sahin D, Sahin A, Akay OM (2016) Comparison of rotational thromboelastography findings in pseudoexfoliation syndrome patients and healthy controls. J Glaucoma 25:879–882CrossRefPubMed Goren Sahin D, Sahin A, Akay OM (2016) Comparison of rotational thromboelastography findings in pseudoexfoliation syndrome patients and healthy controls. J Glaucoma 25:879–882CrossRefPubMed
14.
go back to reference Stanford SN, Sabra A, Lawrence M, Morris RH, Storton S, Wani M, Hawkins K, Williams PR, Potter JF, Evans PA (2015) Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry. J Stroke Cerebrovasc Dis 24:304–311CrossRefPubMed Stanford SN, Sabra A, Lawrence M, Morris RH, Storton S, Wani M, Hawkins K, Williams PR, Potter JF, Evans PA (2015) Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry. J Stroke Cerebrovasc Dis 24:304–311CrossRefPubMed
15.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307CrossRefPubMed Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307CrossRefPubMed
16.
go back to reference Kim KJ, Baek IW, Park KS, Kim WU, Cho CS (2017) Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus 26:88–94CrossRefPubMed Kim KJ, Baek IW, Park KS, Kim WU, Cho CS (2017) Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus 26:88–94CrossRefPubMed
17.
go back to reference Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T, Avalos I, Stein CM (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045–3053CrossRefPubMed Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T, Avalos I, Stein CM (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045–3053CrossRefPubMed
18.
go back to reference Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38:668–674CrossRef Turesson C, Jacobsson L, Bergström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38:668–674CrossRef
19.
go back to reference Lippi G, Emmanuel J, Favaloro EJ, Montagnana M, Franchini M (2010) C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 48:1693–1701PubMed Lippi G, Emmanuel J, Favaloro EJ, Montagnana M, Franchini M (2010) C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 48:1693–1701PubMed
20.
go back to reference Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56:820–830CrossRefPubMed Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56:820–830CrossRefPubMed
21.
go back to reference Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733CrossRefPubMed Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733CrossRefPubMed
22.
go back to reference Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 26:2562–2571PubMed Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 26:2562–2571PubMed
23.
go back to reference Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 17:47–58CrossRefPubMed Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD (2011) Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 17:47–58CrossRefPubMed
24.
go back to reference McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40:640–644CrossRef McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40:640–644CrossRef
25.
go back to reference Schmidt M, Christiansen CF, Horváth-Puhó E, Glynn RJ, Rothman KJ, Sørensen HT (2011) Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost 9:1326–1333CrossRefPubMed Schmidt M, Christiansen CF, Horváth-Puhó E, Glynn RJ, Rothman KJ, Sørensen HT (2011) Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost 9:1326–1333CrossRefPubMed
26.
go back to reference Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, Sylvestre MP, Wynant W, Esdaile JM, Lacaille D (2013) Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 52:68–75CrossRef Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, Sylvestre MP, Wynant W, Esdaile JM, Lacaille D (2013) Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 52:68–75CrossRef
27.
go back to reference Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua Cİ (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 77:98–103CrossRefPubMed Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua Cİ (2018) Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 77:98–103CrossRefPubMed
28.
go back to reference van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151CrossRefPubMedPubMedCentral van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151CrossRefPubMedPubMedCentral
29.
go back to reference Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ (1993) The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2(Suppl. 1):S13–S15PubMed Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ (1993) The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2(Suppl. 1):S13–S15PubMed
30.
go back to reference Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register (2011) Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:1831–1834CrossRefPubMedPubMedCentral Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register (2011) Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:1831–1834CrossRefPubMedPubMedCentral
Metadata
Title
Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM)
Authors
Sümeyye Merve Türk
Döndü Üsküdar Cansu
Hava Üsküdar Teke
Timuçin Kaşifoğlu
O. Meltem Akay
Muzaffer Bilgin
Cengiz Korkmaz
Publication date
01-09-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4134-y

Other articles of this Issue 9/2018

Clinical Rheumatology 9/2018 Go to the issue

Case Based Review

Some days you win

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.